Chapman University School of Pharmacy
Aliso Viejo, California, United States
She holds a Doctor of Pharmacy (PharmD) and recently earned a PhD in Pharmaceutical Economics and Policy. Her research focuses on health economics, particularly the approval, pricing, and utilization of biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). In her dissertation, she examined the economic dynamics of biologic DMARDs and explored how these factors affect RA treatment outcomes and access. She believes that biologics can be transformational in RA treatment, but only if they are affordable and accessible for all individuals living with RA. She is committed to advancing policies that optimize RA management and improve access to life-changing therapies.
1056: Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
Sunday, November 17, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose